Results 231 to 240 of about 1,555,922 (344)

Prolonged morning wake transitions associated with amyloid beta burden: A cross-sectional pilot study. [PDF]

Alzheimers Dement
von Fingerhut G, Makino K, Osuka Y, Ito K, Kato T, Satake S, Shimada H.   +6 more
europepmc   +1 more source

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

BMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou, Jia Liu, Shulin Lai, Suhan Yin, Bingmin Luo, Longquan Shao, Yiyuan Kang   +6 more
wiley   +1 more source

Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer's Disease: Advances and Future Directions. [PDF]

Cells
Dagla I, Gkikas F, Gikas E, Tsarbopoulos A.   +3 more
europepmc   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Amyloid-beta (1-40) peptide is associated with systemic metabolic health. [PDF]

Eur J Clin Invest
Sopova K, Delialis D, Aivalioti E, Georgiopoulos G, Athanasopoulos S, Zervas G, Konstantaki C, Sachse M, Sigl M, Duerschmied D, Tual-Chalot S, Stamatelopoulos K, Stellos K.   +12 more
europepmc   +1 more source

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.

Proceedings of the National Academy of Sciences of the United States of America, 1993
D. Schmechel, A. Saunders, W. Strittmatter, B. Crain, C. Hulette, S. H. Joo, M. Pericak-Vance, D. Goldgaber, A. Roses   +8 more
semanticscholar   +1 more source

The power of many: when genetics met yeasts and high‐throughput

Biological Reviews, EarlyView.
ABSTRACT In recent years, complex technological capabilities have evolved, driven by the need to solve complex and integrative biological questions through global analyses. New equipment allows the scaling up and automation of processes which previously were carried out on a very limited scale.
Víctor A. Tallada, Víctor Carranco
wiley   +1 more source

Using Plasma Amyloid Beta Oligomer to Screen in Alzheimer's Disease: A Pilot Study. [PDF]

Int J Mol Sci
Hsu PC, Yang JY, Huang LC, Yang YH.
europepmc   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease. [PDF]

Cochrane Database Syst Rev
Nonino F, Minozzi S, Sambati L, Del Giovane C, Baldin E, Bassi MC, De Santis C, Gonzalez-Lorenzo M, Vignatelli L, Filippini G, Richard E.   +10 more
europepmc   +1 more source